chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Rash; blisters in hands and feet.; This is a spontaneous report from a contactable consumer (patient reported herself). A 48-year-old non-pregnant female patient received second dose of BNT162B2 (COVID-19, Pfizer, Formulation: Solution for injection, Lot number: EN5318) via an unspecified route of administration to her arm on 19Feb2021 at single dose for Covid-19 immunization. She took COVID prior vaccination. Historical vaccine details included first dose of BNT162B2 (COVID-19, Pfizer, Lot number: EN5318) via an unspecified route of administration to her left arm on 29Jan2021 12:00 PM at single dose for Covid-19 immunization. Facility type vaccine: Nursing Home/Senior Living Facility. Known allergies: Certain foods, Gluten. On 01Feb2021 02:00 PM, the patient experienced rash, blisters in hands and feet. Rash was on both sides of collarbone and sores on head and ears, hairline and back of neck. Seems like follows nerve patters on side of face to head and down arms. It was completely symmetrical. Side effects start 4-5 hours after shot and continue for weeks. Adverse event resulted in Doctor or other healthcare professional office/clinic visit. The patient received CLARITIN and BENADRYL as a treatment in response to the events which did not help. Outcome of the events was not recovered on an unspecified date.
devel mildly itchy morbiliform rash over extremities & trunk began 20 hrs p/vax & lasted 36 hrs; given DPH;
SMALL RED SPOTS APPEARED ON TRUNK 1 WEEK AFTER  RECEIVING VACCINES.  SPREAD TO FACE. PRESENT FOR  2 DAYS.  AFEBRILE.
Cluster of blisters on hand. Tender to touch on 6/28/09. Tx: VALTREX 1GM take 1 tablet 3x day # 15 ORF.
Patient presented to the emergency department on the morning of 5/25/21 with decreased ability to walk and increasing confusion (has mild dementia at baseline), as well as nausea, burping, stomach pains. The patient received 2nd dose of Moderna vaccine at 5PM the evening prior (5/24/21). Also noted to be febrile. Patient's son reports after receiving the second vaccine dose the patient started to take very short steps and took a long time to get anywhere. Had to be held up by his son. Normally he uses a walker to ambulate and get around most places. Also the patient's son reports that he was poor to respond when given directions and will instead stare straight ahead. Son also reported frequent belching with the patient occurring overnight. No vomiting or diarrhea. Patient did have AKI on admission (creatinine 1.7, baseline ~ 1.1) and had been on gabapentin 900mg TID outpatient (this was reduced inpatient) which could have contributed to confusion. The patient did not have any reaction to the first vaccine. Attending physicians attributed acute metabolic encephalopathy, gait abnormality, and fever to Moderna vaccine. Acute encephalopathy was noted to be resolved on 5/27/21. Patient discharge home with home health 6/1/21.
flu for a week; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (flu for a week) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INFLUENZA (flu for a week). At the time of the report, INFLUENZA (flu for a week) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient used concomitant products to treat diabetes, high blood pressure, hypothyroidism and high cholesterol. Patient used Tylenol y Tus (cough syrup) for the treatment.
really tired; heart pounding; couldn't sleep; Headache; sore arm; She couldn't sleep because she was anxious.; almost felt like her blood pressure was up.; Her heart rate is usually 60-65 bpm, but last night it was up to  75-80 bpm; This is a spontaneous report from a contactable consumer. A 33-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, batch/lot number EIC9231), via an unspecified route of administration on 29Dec2020 11:30 at single dose for COVID-19 immunisation.  Medical history was none.  There were no concomitant medications. The patient was calling to report that she got the COVID vaccine yesterday, and she wanted to put input in on the effects she experienced last night. She is a pharmacy transition specialist. She doesn't have a prescribing doctor. A few hours after, she was really tired. She could have fallen asleep at her desk. Then, last night, her heart was like pounding but not beating fast if that makes since. Her heart rate wasn't up that much, but it felt like it was going to come out of her chest. She couldn't sleep because of it. She had a headache. She received the vaccine at 11:30. She is not as tired today. Yesterday, she could have just laid head back and went to sleep. The rest of the side effects started right after dinner. She couldn't sleep because she was anxious. Her heart rate is usually 60-65 bpm, but last night it was up to 75-80 bpm. It almost felt like her blood pressure was up. This happened right around after dinner.  The headache is hanging over into today. It could be still there because she didn't sleep. Her arm is sore still. It isn't serious. The handwriting was bad on her card so it was hard for her to read the lot number. The outcome of the event Headache, sore arm was not resolved, the outcome of the event really tired was resolving, the outcome of the event heart pounding was resolved in Dec2020, while the outcome of the other events was unknown.
Mild Fever (99.6 F), severe headache, hot flashes, chills, fatigue. Started the morning following the vaccination, continued for approximately 24 hours. Spent the whole day in bed.
symptoms started 9/18 with cough and fatigue. tested on 9/23. admitted to hospital 9/24
his best friend died; This is a spontaneous report from a contactable consumer or other non-HCP. A 56-years-old patient of an unspecified gender received unknown dose of bnt162b2 (COMIRNATY, PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Batch number/Lot number was not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The reporter reported that his best friend died on an unspecified date. It was not reported if an autopsy was performed. The outcome of the event was fatal.  The lot number for the vaccine BNT162B2 was not provided and will be requested during follow up.; Reported Cause(s) of Death: his best friend died
p/vax pt hyper & nervous but not unusually for pt that age;brake-out rash; red; irritating; raised non-connecting small red bumps; malaise;rash faded p/10day
Pt. reported approx 1 hr after adm of vaccine she woke up from nap with red itchy eyes, feeling bad, dilated pupils, heart racing and chills. Family member took pt to local ER. She was given BENADRYL, then she was admitted for observation alt persistent HTN. Labs obtained. Pt. discharged on 12-11-14. Pt. recovered.
Information has been received from a physician concerning a 2-month-old patient who was vaccinated with a dose of Rotateq. The physician reported that the patient subsequently developed diarrhea. Unspecified medical attention was sought but no laboratory/diagnostic tests were performed. The patient subsequently recovered. Additional information has been requested.
Patient became flushed, sweaty, and experienced shortness of breath, per his report. This occurred approximately 1 1/2-2 hours after vaccine.
Periods were regular since teenage years, 33-35 days apart, now post vaccine they are 23-25 apart.  No history of nosebleeds EXCEPT during pregnancy, now 2 times a months since vaccine Uterine cramps often, prior to vaccine only during period
BODYACHE; CHILLS; FEVER; NAUSEA; HEADACHE; This spontaneous report received from a patient concerned female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802072,  expiry: UNKNOWN) 1 total administered on 26-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On an unspecified date, the subject experienced bodyache, chills, fever, nausea, and headache. Laboratory data (dates unspecified) included: Body temperature increased (NR: not provided) 102 F. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever, nausea, chills, bodyache and headache was not reported. This report was non-serious.
Headache, Sedation,  ITCHY EYES, ARM PAIN, INCREASE URINATION  Narrative:
This spontaneous report as received from a consumer refers to herself/himself, an adult patient of unknown age and gender with no pertinent medical history, drug reactions or allergies reported. In approximately 2013, reported as "2 years ago", the patient was vaccinated with a dose of ZOSTAVAX (dose, route, lot number and expiration date were not provided) in a pharmacy. Concomitant therapy was not reported. On an unknown date in 2015, reported as "now", the patient experienced shingles of the eye, around the eye and in the eye, so the patient would like to receive part reimbursement. The outcome of the herpes ophthalmic was unknown. Additional information has been requested.
Itchiness all over body 10 minutes after administering shot. Monitored patient for 30minutes, gave 1 diphenhydramine 50mg capsule to take when gets home to her family. Advised patient to call or go to ER if symptoms get worse.
Redness at site of injection measuring 2-3 inches in diameter.  Hot to touch. Tender and swollen.
This spontaneous report has been received from a registered nurse referring to a patient of unknown age or gender. The patient's medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not reported. On an unknown date, the patient was vaccinated with an improperly stored dose of VARIVAX (strength, dose, and anatomical location were not reported), lot # M032493 and expiration date on 06-JUL-2018, for prophylaxis; which experienced a temperature excursion between 6 and 14 Fahrenheit degrees for 3 hours. No previous temperature excursions were reported. Data logger was involved. No adverse effects were reported and no further information was provided. A product quality complaint was not involved. The vaccine was reconstituted with properly stored steril diluent. Additional information has been requested.
Pt developed soreness/pain on the morning of 05/03/2013.  That night he developed a rash accompanied by itching and burning. Pt followed up with the facility on 05/04/2013 and was seen by M.D. and was instructed to take Benadryl to alleviate symptoms.  Pt. was instructed to follow up the next day if symptons persisted.  Pt is going to be seen at Urgent Care today 05/06/2013.
After warm shower & application of about 1 gram, 1% diclofenac gel, noticed mottled/blotchy patch under area of application on lower back. Skin remains mottled in excess of 12 hrs (photos avail).
Patient presented to the hospital on 11/12/22 with shortness of breath that began that day. Patient tested positive for COVID on 11/12/22. Patient expired on 11/19/22.
606 doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Date when vial placed in refrigerator was 04 Nov 2021. No concomitant product reported by reporter. No treatment medication reported by reporter.
Per patient received Flu shot 09/25/15, on Saturday "midday" around lunchtime noticed redness and discomfort. States on Sunday reddened area became itchy but was less red, for which she took 01 BENADRYL. States had palpitations in addition. Came to clinic at 3:00pm for evaluation.
Hives below the injection site across the arm, approximately 2" width. The hives and redness disappeared after 7 days, but the site remained itchy.  Itchiness has persisted intermittently.
Terrible taste in mouth as soon as it was given in the shot.  Tongue began to feel strange.  Pins and needles feeling, itching and burning.  Tingling in hands.  Little swelling in top lip, itching.  Symptoms continue to bother me.
Short-term memory loss; This is a spontaneous report from a contactable nurse (the patient). A 54-year-old male patient receive his second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3302, expiration date: 31May2021), via an unspecified route of administration on 16Jan2021 06:40 at a single dose for COVID-19 immunization. The patient's medical history was not reported. There were no concomitant medications. The patient previously received his first dose of COVID-19 vaccine with lot #: EJ1685. It was reported that the patient received his second dose of vaccine and he wanted to report a strange side effect of short-term memory loss on 16Jan2021. He does not think that he has it now at the time of report but it never happened before. He mentioned he was walking down the hospital and he had a momentary memory loss. He did not know where he was going. He lost complete direction. He has worked in that hospital for 20 years. The outcome of the event was unknown.
felt some nausea; he "felt off" / had a similar feeling, kind of off, he didn't feel all there; he also had some trouble with dinner; This is a spontaneous report received from a contactable reporter (Consumer) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date Mar2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NAUSEA (non-serious) with onset Mar2021, outcome "unknown", described as "felt some nausea"; FEELING ABNORMAL (non-serious) with onset Mar2021, outcome "unknown", described as "he "felt off" / had a similar feeling, kind of off, he didn't feel all there"; DECREASED APPETITE (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "he also had some trouble with dinner".  Additional Information: The patient stated that he received the Pfizer COVID-19 vaccine last Tuesday (Mar2021). On Wednesday (Mar2021) during a 3 hour stretch, he felt some nausea, and he "felt off". He stated that he was more comfortable resting his head or laying down. On Thursday and Friday (Mar2021), he was okay. On Saturday (Mar2021), he had a similar feeling, kind of off, he didn't feel all there, and he also had some trouble with dinner. Yesterday (Mar2021), he had all 3 meals but still felt off. Today (Mar2021), his appetite was fine and he didn't feel so off. He wanted to know if there had been reports of lingering symptoms after 72 hours.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
rash; redness at injection site; very tired; muscle and arm hurts, aches and pain; Slept most of the day; This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 012L20A) for COVID-19 vaccination.     NO Medical History Information was reported.  Concomitant products included PREDNISONE, LOSARTAN, THYROID (ARMOUR THYROID) and ATORVASTATIN for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Feb-2021, the patient experienced RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day). At the time of the report, RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day) outcome was unknown.            Treatment information was not provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 21-Feb-2021 and was forwarded to Moderna on 22-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 012L20A) for COVID-19 vaccination.     NO Medical History Information was reported.  Concomitant products included PREDNISONE, LOSARTAN, THYROID (ARMOUR THYROID) and ATORVASTATIN for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Feb-2021, the patient experienced RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day). At the time of the report, RASH (rash), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (very tired), MYALGIA (muscle and arm hurts, aches and pain) and ASTHENIA (Slept most of the day) outcome was unknown.            Treatment information was not provided.
States that a 8 p.m. she started to notice hoarseness in her voice and started with a deep persistant cough.  She then when on to have difficulty breathing, tightness in her chest, hives, paleness, weakness, tachycardia, dizziness, abdominal cramping, shortness of breath, and she "shook uncontrollably".  She called 911 and was taken to hospital where she was admitted to the ICE Thursday evening and was moved to a regular room on Friday evening and was discharged on Saturday. Discharge summary states angina. msv
sinus infection; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received the first dose of BNT162B2 via an unspecified route of administration on 2020 at a single dose for COVID-19 immunization. There were no medical history and no concomitant medications. The patient, who worked in a hospital laboratory, stated that after the first dose, he got a sinus infection on 24Dec2020. He went through antibiotics for a week for the sinus infection which was completed by the second dose. The outcome of the event was recovered on 31Dec2020.  Information about lot/batch number has been requested.
Patient reported to be unresponsive on the morning after receiving his second dose of Moderna COVID-19 vaccine.  Patient had expired during the night.
Pt presents to clinic with left leg reddened and warm to touch. No swelling noted at this time. Mom states it had some swelling last night. No fever noted. Immunization given 7/17/02. Dx: Localized reaction to DTAP.
I was on a cruise and had a sore throat, coughing, runny nose, high temperature, was shaking. I went to medical to find out what was causing me feel so bad. They ran an influenza and COVID-19 test the COVID-19 test came back positive. They gave me NYQUIL to help me sleep. I was in quarantine until we docked, then I stayed in a hotel until I tested negative to fly home.
No adverse event; Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) in a 65-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 042J21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 22-Feb-2022, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 22-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 day beyond use date).    Concomitant product use was not provided by the reporter. More or less 170 - monovalent and 20 bivalent doses had been administered which were beyond the 30 day beyond use date. Vaccine administered on 23-Feb-2022 with lot number 042J21A after 30 days BUD date which was 17-Feb-2022. Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-704416 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jan-2023: Live follow up has been appended.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704416:Master case
This spontaneous report as received from a physician refers to unspecified number of patients of unknown age. Current conditions and medical history was not reproted. On an unknown date, the patients were vaccinated with M-M-R II (dose, route, lot number and frequency were not reported). Concomitant medications were not reported. On an unknown date, M-M-R II was improperly stored for an unspecified amount of time and administered to an unspecified number of patients. No adverse effects reported. The outcome was unknown. Product quality complaint was not reported. No further information provided. This is one of several reports received from the same reporter. Additional information has been requested.